Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 18-80~2. Male and female subjects of all races and ethnicities including Spanish speaking subjects~3. Cirrhosis of any cause~4. Any grade of hepatic encephalopathy (1-4)~5. A legally authorized representative has to be able and willing to comply with all protocol procedures and to understand, sign and date an informed consent document, and authorize access to protected health information on the subjects behalf~Exclusion Criteria:~1. Acute liver failure~2. Structural brain lesions (as indicated by computed tomography imaging if available and confirmed by neurological exam)~3. Other causes of altered mental status (i.e. not meeting the definition of hepatic encephalopathy)~4. Previous use of rifaximin or neomycin in past 7 days~5. Prisoners~6. Pregnancy~7. \<18 years old~8. Serum sodium \<125 mEq/L~9. Receiving \> 1 dose of lactulose prior to enrollment~10. Uncontrolled infection with hemodynamic instability requiring vasopressors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) (Type: ACTIVE_COMPARATOR): None
- Lactulose (Type: OTHER): Per standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).